European Pharmaceutical Review

SEPTEMBER 14, 2023

Market uncertainty Rising operational costs, stiffening competition, ongoing patent expirations, evolving environmental and social governance requirements and increasing pressure on drug prices mean the industry will have to navigate thoughtfully to be successful amid this complicated mix of financial and strategic risks.

Drug Development 98

Drug Development Drug Pricing Communication 98

Pharmaceutical Technology

JUNE 29, 2022

Almost 40 years since it was instituted, some have described the FDA’s orphan drug program, which is meant to foster innovation, as “ one of the most successful US legislative actions in recent history ”. However, extended market exclusivity is often associated with high drug pricing and limited patient access.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies Drug Pricing Drug Development 98

Pharmaceutical Technology

MAY 29, 2008

Important elements within this expectation are the build up of strong contributions from Rotarix, Cervarix and Tykerb, while the outlook for GSK’s important asthma franchise becomes less clear beyond 2010. It has struck a large number of such deals in the last couple of years and we expect the number to continue to increase.

Drug Pricing 40

Drug Pricing Diabetes Drug Development 40

European Pharmaceutical Review

DECEMBER 26, 2023

Production cost is currently a fundamental concern for many gene therapy developers, particularly given that some treatments cost millions of dollars per single dose (eg, $3.5 Available from: [link] About the author Kai Lipinski, PhD joined Vibalogics, now ReciBioPharm, in 2010 as Head of Cell Culture and Virus Production.

Drug Pricing 98

Drug Pricing Packaging Vaccines Drug Development 98

Safe Biologics

SEPTEMBER 11, 2023

September 11, 2023 The Centers for Medicare & Medicaid Services (CMS) recently announced the first 10 drugs selected under its Medicare drug price “negotiation” plan, authorized by the Inflation Reduction Act (IRA) signed in to law last year. 1] 90% of new cancer drugs are available in the U.S.

Drug Pricing 150

Drug Pricing Biosimilars Vaccines Drug Development 150